酒石酸托特罗定缓释片改善留置双J管患者相关的临床症状及生活质量的疗效观察

Effect of Tolterodine in Improving Symptoms and Quality of Life of Patients with Indwelling Double-J Ureteral Stents

目的:探讨酒石酸托特罗定缓释片改善留置双J管患者相关的临床症状及生活质量的疗效。方法:60例(男30例,女30例,平均47.1岁)上尿路手术后并留置双J管患者被随机分为两组,治疗组(n=30)给予酒石酸托特罗定缓释片4 mg,1次/d,口服1个月;对照组(n=30)未给予干预治疗。所有患者在置管4周后均随访并完成输尿管支架管相关症状问卷。结果:所有患者置管4周平均尿路症状指数评分(19.3:28.3),平均疼痛指数评分(13.7:19.5),平均健康指数评分(8.3:13.2),性功能指数评分(2.2:2.8),治疗组均较对照组有明显改善(P<0.01)。结论:酒石酸托特罗定缓释片能明显改善留置输尿管支架管患者尿路症状及生活质量。

Objective：To evaluate the effect of Tolterodine in improving symptoms and quality of life of patients with indwelling double-J ureteral stents. Methods： 60 patients （30 men and 30 women; mean age 47.1 years） ,with unilateral ureteral obstruction due to urinary stone undergoing to ureteral stenting after treatment of stone disease ,were prospectively randomized into two groups. Treatment group included 30 patients who received 4 mg of Tolterodine, once daily for 4 weeks, and control group consisted of 30 patients who did not give intervention for the same period. All patients completed a validated Ureteral Stent Symptom Questionnaire （USSQ） after 4 weeks. Results： The mean urinary symptom index score was 19.3 in treatment group and 28.3 in control group （P〈0.01）. Stent-related pain was reported by 43% of patients in treatment group and 69% of patients control group （P〈0.01）. The mean pain index score was 13.7 in treatment group and 19.5 in control group （P〈0.01）. The mean general health index score was 8.3 in treatment group and 13.2 in control group, Among sexually active patients, the mean sexual score was 2.2 in treatment group and 2. 8 in control group （P〈0. 01）. Conclusions： Tolterodine improved a subset of stent-related urinary symptoms and quality of life.